Lila Sciences raises $235 million to expand AI-driven research platform

16 September 2025

Lila Sciences has secured $235 million in series A financing, co-led by Braidwell and Collective Global, at a valuation of about $1.23 billion. The Massachusetts-based company, founded by Flagship Pioneering in 2023, is building an artificial intelligence platform designed to automate and accelerate the scientific method across multiple disciplines.

The latest financing follows a $200-million seed round in March and will be used to hire staff and open new sites in Boston, San Francisco and London. These locations will house the company’s so-called AI Science Factories, facilities that integrate AI, robotics and laboratory systems to design and run experiments at scale. Lila says these factories have already conducted hundreds of thousands of studies across life science, chemistry and materials science.

Building autonomous science at scale

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >




Today's issue

Company Spotlight



More Features in Pharmaceutical